Results 161 to 170 of about 75,992 (272)

Authors' Reply to Letter to the Editor: Sequential Ramucirumab Plus Docetaxel After PD‐1 Inhibitors

Cancer Science, EarlyView.
Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama   +2 more
wiley   +1 more source

Nivolumab Enhances the Cytotoxicity of Chemotherapeutic Agents in A549 Lung Adenocarcinoma Cell Lines. [PDF]

Curr Issues Mol Biol
Okşak N, Karhan O.
europepmc   +1 more source

Pathological Complete Response to Nivolumab Plus Ipilimumab Combination Therapy in Advanced Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus. [PDF]

IJU Case Rep
Tsuchiya T, Kimura G, Takeda H, Akatsuka J, Hasegawa H, Toyama Y, Sakatani T, Shimizu A, Ohashi R, Kondo Y.   +9 more
europepmc   +1 more source

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Hepatology Research, EarlyView.
ABSTRACT Aim Systemic therapy is required for unresectable hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab (ATZ/BEV) is the recommended first‐line treatment for HCC; however, the development of anti‐drug antibodies (ADAs) against ATZ may impair its therapeutic efficacy. Although ADAs have been reported in other cancers treated with immune
Keishi Ouchi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Kotaro Doi, Kengo Watanabe, Tomoya Sasazaki, Atsushi Masamune   +8 more
wiley   +1 more source

Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study. [PDF]

Res Rep Urol
Furubayashi N, Tsujita J, Takayama A, Shiraishi Y, Nakamura M, Negishi T.   +5 more
europepmc   +1 more source

PD‐L1‐Inhibitor‐Associated Hidradenitis Suppurativa

Journal of Cutaneous Pathology, EarlyView.
Annie Jin, Katherine T. Steele, Emily Y. Chu   +2 more
wiley   +1 more source

Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Immunosuppressive disease was associated with reduced overall survival, while anticoagulant use was linked to prolonged progression‐free survival in advanced cutaneous squamous cell carcinoma treated with immune checkpoint inhibitors. Host‐related factors may modulate immunotherapy efficacy and warrant prospective validation.
Glenn Geidel, Sabrina Bänsch, Laura Adam, Nathan Fekade, Alessandra Rünger, Tim Zell, Daniel J. Smit, Julian Kött, Isabel Heidrich, Michael Weichenthal, Selma Ugurel, Ulrike Leiter, Peter Mohr, Alexandra Geusau, Stephan Grabbe, Markus V. Heppt, Ralf Gutzmer, Jochen Utikal, Jan‐Christoph Simon, Sebastian Haferkamp, Laura Susok, Bastian Schilling, Edgar Dippel, Imke von Wasielewski, Jessica C. Hassel, Carola Berking, Stefan W. Schneider, Christoffer Gebhardt   +27 more
wiley   +1 more source

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn, Alexandre O. Gérard, Maëlys Labat, Zoe Apalla, Wouter van Binsbergen, Dimitra Koumaki, Valerian Rivet, Frederic Dezoteux, Damien Giacchero, Michael R. Ardern‐Jones, Kara Heelan, Jesse P. Hirner, Ander Mayor, Mariette Labots, Markus V. Starink, Conny J. van der Laken, Vincent Sibaud, Yannick S. Elshot   +17 more
wiley   +1 more source

Exceptional therapeutic benefit of imatinib in cKIT‐mutated mucosal melanoma followed by a KIT mutation loss

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Hannah Zillikens, Corinna Scheib, Vicky Peller, Christina Müller, Sebastian Bauer, Ina Pretzell, Klaus Griewank, Antje Sucker, Eva Hadaschik, Felicitas Guntrum, Sven Holger Baum, Alexander Roesch, Selma Ugurel, Dirk Schadendorf, Lisa Zimmer, Elisabeth Livingstone   +15 more
wiley   +1 more source

Reflex Syncope With Complete Heart Block Triggered by Swallowing in a Patient on Immune Checkpoint Inhibitor Therapy

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) are now standard of care for most advanced solid tumors. While effective, they are associated with immune‐related adverse events (irAEs), including rare autonomic complications. We present a patient with metastatic lung adenocarcinoma receiving nivolumab and ipilimumab who developed reflex syncope with ...
Ashley Bouzon, Michael Oropesa, Bardia Adibmoradi, Daniel Weitz   +3 more
wiley   +1 more source